SCHEMBL2474110

SCHEMBL2474110

Nc1ccccc1NC(=O)c1ccc(CN(CCc2ccncc2)C(=O)Nc2ccc3c(c2)OCCO3)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.55
HDAC2 Q92769 4/20 0.53
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NAMPT P43490 2/20 0.50
HSD17B10 Q99714 1/20 0.50
HDAC3 O15379 5/20 0.49
HDAC6 Q9UBN7 3/20 0.49
HDAC4 P56524 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
NPC1 O15118 3/20 0.45
TP53 P04637 2/20 0.43
MAPT P10636 1/20 0.43
AHR P35869 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2497124 0.94 HDAC1 (0.59) HDAC1HDAC2RAB9ASMN1; SMN2NAMPT
SCHEMBL2473986 0.88 HDAC1 (0.59) HDAC1HDAC2RAB9AHDAC3HDAC6
SCHEMBL2474298 0.87 HDAC1 (0.58) HDAC1HDAC2RAB9ASMN1; SMN2HDAC3
SCHEMBL3832860 0.86 NAMPT (0.46) HDAC1RAB9ASMN1; SMN2NAMPTHSD17B10
SCHEMBL2473290 0.86 HDAC1 (0.57) HDAC1HDAC2RAB9ASMN1; SMN2HDAC3
SCHEMBL3831005 0.86 HDAC1 (0.53) HDAC1HDAC2NAMPTHDAC3HDAC6
SCHEMBL2476825 0.85 HDAC1 (0.56) HDAC1HDAC2RAB9ASMN1; SMN2HDAC3
SCHEMBL3835117 0.84 HDAC1 (0.60) HDAC1HDAC2RAB9ANAMPTHSD17B10
SCHEMBL3835176 0.83 ALDH1A1 (0.56) HDAC1HDAC2RAB9ASMN1; SMN2HSD17B10
SCHEMBL2496816 0.83 HDAC1 (0.73) HDAC1HDAC2RAB9ASMN1; SMN2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885HDAC2 129/4885RAB9A 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.